108229-82-9

Basic information

• Product Name: 6-bromo-2,3-dichloroquinoxaline
• Synonyms: 6-bromo-2,3-dichloroquinoxaline;7-bromo-2,3-dichloroquinoxaline
• CAS NO: 108229-82-9
• Molecular Formula: C₈H₃BrCl₂N₂
• Molecular Weight: 277.9328
• Mol File: 108229-82-9.mol

Chemical Properties

• Boiling Point: 326.707 °C at 760 mmHg
• Flash Point: 151.387 °C
• Appearance: /
• Density: 1.852 g/cm³
• Refractive Index: 1.696
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: -6.33±0.48(Predicted)
• CAS DataBase Reference: 6-bromo-2,3-dichloroquinoxaline(CAS DataBase Reference)
• NIST Chemistry Reference: 6-bromo-2,3-dichloroquinoxaline(108229-82-9)
• EPA Substance Registry System: 6-bromo-2,3-dichloroquinoxaline(108229-82-9)

Safety Data

• Hazardous Substances Data: 108229-82-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Drug Development:
6-Bromo-2,3-dichloroquinoxaline is used as a key building block in the synthesis of various heterocyclic compounds and drug candidates. Its potential applications in the development of pharmaceutical drugs are attributed to its wide range of biological activities, including antimicrobial and anticancer properties.
Used in Organic Synthesis:
6-Bromo-2,3-dichloroquinoxaline is utilized as a versatile intermediate in organic synthesis. Its unique structure and reactivity make it an important compound for the synthesis of various heterocyclic compounds, which are often found in pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Medicinal Chemistry Research:
6-Bromo-2,3-dichloroquinoxaline is employed as a valuable research tool in medicinal chemistry. Its potential pharmaceutical applications and biological activities make it an essential compound for studying the structure-activity relationships of various drug candidates and for the development of novel therapeutic agents.

InChI:InChI=1/C8H3BrCl2N2/c9-4-1-2-5-6(3-4)13-8(11)7(10)12-5/h1-3H

Upstream product

• 1575-37-7 4-Bromo-benzene-1,2-diamine 
• 1910-90-3 6-bromo-1,4-dihydro-quinoxaline-2,3-dione 
• 95-92-1 oxalic acid diethyl ester 

Downstream Products

• 1374748-92-1 2-(6-bromo-3-(4-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetic acid 
• 1374748-93-2 2-(6-bromo-3-(4-bromophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetic acid 
• 1374748-94-3 2-(6-bromo-3-(4-bromo-2-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetic acid 
• 1374748-85-2 2-(7-bromo-3-(4-bromo-2-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetic acid 
• 1374748-84-1 2-(7-bromo-3-(4-bromophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetic acid 
• 1374748-83-0 2-(7-bromo-3-(4-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetic acid 
• 1374748-68-1 methyl 2-(6-bromo-3-(4-bromo-2-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetate 
• 1374748-67-0 methyl 2-(6-bromo-3-(4-bromophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetate 
• 1374748-66-9 methyl 2-(6-bromo-3-(4-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetate 
• 1374748-59-0 methyl 2-(7-bromo-3-(4-bromo-2-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetate 
• 1374748-58-9 methyl 2-(7-bromo-3-(4-bromophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetate 
• 1374748-57-8 methyl 2-(7-bromo-3-(4-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetate 
• 120317-45-5 (7-Bromo-2-imino-thiazolo[4,5-b]quinoxalin-3-yl)-[1-(4-chloro-phenyl)-meth-(Z)-ylidene]-amine 
• 120317-41-1 7-Bromo-2-phenyl-10-thia-1,3,3a,4,9-pentaaza-pentaleno[1,2-b]naphthalene 

Relevant articles and documents

A One-pot Facile Synthesis of 2,3-Dihydroxyquinoxaline and 2,3-Dichloroquinoxaline Derivatives Using Silica Gel as an Efficient Catalyst

An efficient one-pot reaction has been developed for the synthesis of 2,3-dichloroquinoxaline derivatives 3a–n. The reaction was performed in two steps via a silica gel catalyzed tandem process from o-phenylenediamine and oxalic acid, followed by addition of phosphorus oxychloride (POCl3). A variety of 2,3-dichloroquinoxalines have been obtained in good to excellent overall yields. Eight known compounds 3a–3h were characterized by IR, 1H-NMR, and mass spectroscopies. Compounds 3i–3n without spectroscopic data were characterized by IR, 1H-NMR, 13C-NMR, and mass spectroscopies.

Revisiting the Quinoxalinedione Scaffold in the Construction of New Ligands for the Ionotropic Glutamate Receptors

More than two decades ago, the quinoxalinedione scaffold was shown to act as an α-amino acid bioisoster. Following extensive structure-activity relationship (SAR) studies, the antagonists DNQX, CNQX, and NBQX in the ionotropic glutamate receptor field were identified. In this work, we revisit the quinoxalinedione scaffold and explore the incorporation of an acid functionality in the 6-position. The SAR studies disclose that by this strategy it was possible to tune in iGluR selectivity among the AMPA, NMDA, and KA receptors, and to some extent also obtain full receptor subtype selectivity. Highlights of the study of 44 new analogues are compound 2m being a high affinity ligand for native AMPA receptors (IC50= 0.48 μM), analogues 2e,f,h,k,v all displayed selectivity for native NMDA receptors, and compounds 2s,t,u are selective ligand for the GluK1 receptor. Most interestingly, compound 2w was shown to be a GluK3-preferring ligand with full selectivity over native AMPA, KA and NMDA receptors.

Novel molecular targeting anti-tumor aza-steroid derivative based on lipid toxicity and preparation and application thereof

The invention provides a novel molecular targeting anti-tumor aza-steroid derivative based on lipid toxicity and a preparation method and application thereof, and belongs to the field of chemical medicines. The derivative is a compound as shown in a formula I, or a salt thereof, or a stereoisomer thereof. The compound is low in toxicity or basically non-toxic to normal cells, has an obvious inhibition effect to tumor cell lines, particularly has good lipid toxicity selectivity to tumor cells such as liver cancer, lung cancer and the like in vivo, and has an obvious inhibition effect; meanwhile, the compound can effectively activate SREBP1 and PPAR gamma, inhibit lipid transport MTTP, cause lipid aggregation in tumor cells and cause lipid toxicity of the tumor cells. The compound can be used for treating liver cancer, lung cancer and the like in a molecular targeting manner, is low in toxicity or even non-toxic, and has a good application prospect.

HETEROCYCLIC DERIVATIVES AND USE THEREOF

The present invention relates to novel heterocyclic compounds useful in preparing drugs for the treatment of diseases associated with various functions of the histamine 4 receptor. Specifically, these drugs are useful in the prevention or treatment of inf